Aziz Yazar

651 total citations
22 papers, 508 citations indexed

About

Aziz Yazar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Aziz Yazar has authored 22 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Aziz Yazar's work include Gastrointestinal motility and disorders (3 papers), Lung Cancer Research Studies (3 papers) and Peptidase Inhibition and Analysis (3 papers). Aziz Yazar is often cited by papers focused on Gastrointestinal motility and disorders (3 papers), Lung Cancer Research Studies (3 papers) and Peptidase Inhibition and Analysis (3 papers). Aziz Yazar collaborates with scholars based in Türkiye, Spain and Germany. Aziz Yazar's co-authors include Cengiz Pata, Arzu Kanık, Mehmet Emin Erdal, Esen Akbay, M. Erem Çalıkoğlu, Gürbüz Polat, Waldemar Bojara, Alfried Germing, A. Mumme and Andreas Mügge and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The American Journal of Gastroenterology.

In The Last Decade

Aziz Yazar

21 papers receiving 494 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aziz Yazar Türkiye 10 156 112 103 97 87 22 508
Branka Filipović Serbia 13 109 0.7× 129 1.2× 41 0.4× 49 0.5× 140 1.6× 41 525
Jakub Włodarczyk Poland 11 95 0.6× 126 1.1× 47 0.5× 99 1.0× 39 0.4× 51 426
Gennaro Martines Italy 12 51 0.3× 222 2.0× 107 1.0× 64 0.7× 151 1.7× 61 550
Heiko Fruehauf Switzerland 18 374 2.4× 381 3.4× 82 0.8× 60 0.6× 46 0.5× 34 835
Michael Peters United States 11 112 0.7× 248 2.2× 94 0.9× 83 0.9× 136 1.6× 15 585
Tova Rainis Israel 14 67 0.4× 303 2.7× 135 1.3× 74 0.8× 41 0.5× 34 559
J. O. Stadaas Norway 15 207 1.3× 415 3.7× 159 1.5× 44 0.5× 49 0.6× 58 701
Naoya Watanabe Japan 10 46 0.3× 103 0.9× 31 0.3× 57 0.6× 108 1.2× 44 440

Countries citing papers authored by Aziz Yazar

Since Specialization
Citations

This map shows the geographic impact of Aziz Yazar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aziz Yazar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aziz Yazar more than expected).

Fields of papers citing papers by Aziz Yazar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aziz Yazar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aziz Yazar. The network helps show where Aziz Yazar may publish in the future.

Co-authorship network of co-authors of Aziz Yazar

This figure shows the co-authorship network connecting the top 25 collaborators of Aziz Yazar. A scholar is included among the top collaborators of Aziz Yazar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aziz Yazar. Aziz Yazar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ayla, Şule, Nil Molinas Mandel, Metin Özkan, et al.. (2020). Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy. Journal of Oncology. 2020. 1–7. 4 indexed citations
3.
Oyan, Başak, et al.. (2018). Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.. Journal of Clinical Oncology. 36(15_suppl). e24306–e24306. 2 indexed citations
4.
Mandel, Nil Molinas, Zafer Gülbaş, Barkın Berk, et al.. (2017). Cytolytic tests with hyperimmune patient sera is a good prognostic tool in racotumomab immunotherapy in advanced non-small cell lung cancer. SHILAP Revista de lepidopterología. 3(5). 1 indexed citations
5.
Okan, Gökhan, Pervin Vural, Ümit İnce, et al.. (2012). Muir-Torre syndrome: A case report and review of the literature. The Turkish Journal of Gastroenterology. 23(4). 394–398. 6 indexed citations
6.
Oğuz, Hilal, et al.. (2011). Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer.. PubMed. 97(3). 286–9. 7 indexed citations
7.
Oğuz, Hilal, et al.. (2011). Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer. Tumori Journal. 97(3). 286–289. 9 indexed citations
8.
Gotzmann, Michael, Alfried Germing, Michael Lindstaedt, et al.. (2009). Short-term effects of transcatheter aortic valve implantation on neurohormonal activation, quality of life and 6-minute walk test in severe and symptomatic aortic stenosis. Heart. 96(14). 1102–1106. 76 indexed citations
9.
Üstüner, Zeki, Pınar Saip, Vildan Yasasever, et al.. (2008). Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Medical Oncology. 25(4). 394–399. 32 indexed citations
10.
Aydıner, Adnan, Filiz Koşar, Atilla Gürses, et al.. (2007). Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: A phase II study. Lung Cancer. 58(2). 246–252. 9 indexed citations
11.
Ağaoğlu, Fulya, Merdan Fayda, Yavuz Dizdar, et al.. (2005). Primary uterine lymphoma: Case report and literature review. Australian and New Zealand Journal of Obstetrics and Gynaecology. 45(1). 88–89. 6 indexed citations
12.
Yazar, Aziz, et al.. (2005). The Urinary 5-Hydroxyindole Acetic Acid and Plasma Nitric Oxide Levels in Irritable Bowel Syndrome: A Preliminary Study. Scottish Medical Journal. 50(1). 27–29. 14 indexed citations
13.
Yazar, Aziz, Mert Başaran, Yavuz Dizdar, et al.. (2004). Relapse of non‐Hodgkin's lymphoma confined to the corpus uteri. Australian and New Zealand Journal of Obstetrics and Gynaecology. 44(3). 273–274. 1 indexed citations
14.
Karaca, Çetin, et al.. (2004). Is lower socio-economic status a risk factor for Helicobacter pylori infection in pregnant women with hyperemesis gravidarum?. PubMed. 15(2). 86–9. 32 indexed citations
15.
Yazar, Aziz, Oben Döven, Sibel Atış, et al.. (2003). Systolic Pulmonary Artery Pressure and Serum Uric Acid Levels in Patients with Hyperthyroidism. Archives of Medical Research. 34(1). 35–40. 30 indexed citations
16.
Pata, Cengiz, Aziz Yazar, Engin Altıntaşž, et al.. (2003). Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis.. PubMed. 50(51). 794–7. 12 indexed citations
17.
Pata, Cengiz, et al.. (2002). Serotonin Transporter Gene Polymorphism in Irritable Bowel Syndrome. The American Journal of Gastroenterology. 97(7). 1780–1784. 118 indexed citations
18.
Yazar, Aziz, et al.. (2002). Effects of glibenclamide, metformin and insulin on the incidence and latency of death by oubain-induced arrhythmias in mice. Pharmacological Research. 45(3). 183–187. 7 indexed citations
19.
Büyükafşar, Kansu, et al.. (2001). Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats. Pharmacological Research. 44(4). 321–328. 35 indexed citations
20.
Yazar, Aziz. (2001). Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome. The American Journal of Gastroenterology. 96(5). 1511–1516. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Branka Filipović Breakdown of academic impact, for papers by Jakub Włodarczyk Breakdown of academic impact, for papers by Gennaro Martines Breakdown of academic impact, for papers by Heiko Fruehauf Breakdown of academic impact, for papers by Michael Peters Breakdown of academic impact, for papers by Tova Rainis Breakdown of academic impact, for papers by J. O. Stadaas Breakdown of academic impact, for papers by Naoya Watanabe
Rankless by CCL
2026